Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

Sep 8, 2024Diabetes, obesity & metabolism

Time spent in target blood sugar range from self-monitoring in people with type 2 diabetes starting iGlarLixi: Combined analysis of three clinical trials

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

The fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improved derived time-in-range (dTIR) by 25.7% compared to 15.8% for insulin glargine alone.

iGlarLixi showed greater improvements in dTIR from baseline to end of treatment compared to insulin glargine, lixisenatide, and glucagon-like peptide-1 receptor agonists.
At the end of treatment, the derived time-below-range (dTBR) was low across all treatment groups, with iGlarLixi showing a dTBR of 0.71%.
Improvements in LS means dTIR were consistent in participants younger than 65 years and those aged 65 years or older when treated with iGlarLixi.
The findings suggest iGlarLixi may be associated with favorable glucose control in individuals with type 2 diabetes.

AI simplified

AIM: To evaluate the efficacy of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) using derived time-in-range (dTIR).

METHODS: Participant-level data from LixiLan-L, LixiLan-O and LixiLan-G were pooled and dTIR (70-180 mg/dL), derived time-above-range (> 180 mg/dL) and derived time-below-range (dTBR; < 70 mg/dL) were calculated from participant seven-point self-monitored blood glucose profiles.

RESULTS: This pooled analysis included data from 2420 participants receiving iGlarLixi (n = 1093), iGlar (n = 836), Lixi (n = 234) or a glucagon-like peptide-1 receptor agonist (GLP-1 RA) (n = 257). Numerically greater improvements in least square (LS) means dTIR were seen from baseline to end of treatment (EOT) with iGlarLixi (25.7%) versus iGlar (15.8%), Lixi (11.7%) or GLP-1 RA (16.2%). At EOT, the mean (standard deviation) dTBR was 0.71% ± 3.4%, 0.61% ± 3.2%, 0.08% ± 1.0% and 0.0% ± 0.0% for iGlarLixi, iGlar, Lixi and GLP-1 RA, respectively. In a subgroup analysis, participants aged younger than 65 years (n = 1690) and 65 years or older (n = 713) showed numerically greater improvements in LS means dTIR from baseline to EOT with iGlarLixi versus iGlar, Lixi or GLP-1 RA.

CONCLUSIONS: iGlarLixi achieved improvements in dTIR, with low dTBR values, providing further evidence to inform clinical outcomes with the use of iGlarLixi.

Full Text

Full text is available at the source.

View full text ↗

Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief